Related Links
Statistics
| Number of Journals | 8 |
| Number of Issues | 51 |
| Number of Articles | 379 |
| Article View | 101,549 |
| PDF Download | 66,156 |
evaluation of the effectiveness of ivermectin in combination with standard treatment in suspected COVID-19 patients: A double-blind randomized clinical trial19 | ||
| Advances in Pharmacology and Therapeutics Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 08 September 2025 | ||
| Document Type: Clinical Trial | ||
| Author | ||
| zohreh akhoundimeybodi* | ||
| Fellowship of Prevention and Control of Nosocomial Infections,Infectious Diseases research center Shahid sadoughi hospital,shahid sadoughi university of medical sciences,yazd,iran | ||
| Abstract | ||
| Background: Ivermectin may be associated with inhibition of nuclear transport, a mechanism that may be effective against SARS-CoV-2. In this study, we investigated the effectiveness of ivermectin in combination with standard treatment in suspected or probable COVID-19 patients. Materials and methods: This study was a double-blind randomized controlled clinical trial . 50 patients aged 18 to 60 suspected of having COVID-19 based on clinical symptoms and COVID PCR, who are candidates for outpatient treatment , are randomly divided into two intervention groups including ivermectin along with standard treatment and a control group including placebo treatment along with standard treatment. The patients were contacted on the first, third, seventh, and fourteenth day and the symptoms were asked according to the questionnaire. Results: Comparison of NYHA classes between the first day and the fourteenth day using the Wilcoxon test showed that the NYHA classes in the fourteenth group had a significant decrease compared to the first day (P≤0.05). Changes in cough frequency between the two groups during 14 days were statistically significant (P≤0.05). Changes in the frequency of shortness of breath between the two groups during 14 days were statistically significant (P≤0.05). Changes in the frequency of fever, headache, dizziness, myalgia, and the need to receive painkillers between the two groups during 14 days were not statistically significant. Changes in the frequency of nausea and vomiting between the two groups during 14 days were statistically significant (P≤0.05). Conclusion: In the end, we concluded that using ivermectin in patients with mild to moderate clinical conditions of COVID-19 was effective in the subsequent improvement of the clinical symptoms of patients who were also receiving standard treatment and patients' symptoms have improved in a shorter period. | ||
| Keywords | ||
| covid-19; ivermectin; shortness of breath; SARS-CoV-2 | ||
|
Statistics Article View: 3 |
||